Press Releases

Date Title and Summary View
Toggle Summary MediWound Reports First Quarter 2021 Financial Results
First Quarter Revenues of $5.8 Million , an Increase of 32% Year-over-Year Conference call begins today at 8:30 am ET   YAVNE, Israel , May 05, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation bio-therapeutics solutions
View HTML
Toggle Summary MediWound to Report First Quarter 2021 Financial Results and Host a Conference Call and Webcast on May 5, 2021
YAVNE, Israel, April 26, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company focused on next-generation bio-therapeutic solutions for tissue repair and regeneration, today announced that the Company will release its financial results for the first
View HTML
Toggle Summary MediWound Enrolls First Patient in Phase 2 Pharmacology Study of EscharEx
Data Expected Second-Half 2021 YAVNE, Israel , April 22, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation bio-therapeutics solutions for tissue repair and regeneration, today announced it has enrolled the first patient
View HTML
Toggle Summary MediWound Hosting Analyst Day Webinar on EscharEx – Enzymatic Debridement Agent for Chronic Wounds
Webinar To Be Held on Tuesday, March 30th at 10am Eastern Time YAVNE, Israel , March 24, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company focused on next-generation bio-therapeutic solutions for tissue repair and regeneration, today announced that
View HTML
Toggle Summary MediWound to Participate in Upcoming March Investment Conferences
YAVNE, Israel , Feb. 25, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company focused on next-generation bio-therapeutic solutions for tissue repair and regeneration, today announced that the Company will present at the following virtual investor
View HTML
Toggle Summary MediWound Reports Fourth Quarter and Full-Year 2020 Financial Results
Fourth Quarter Revenues of $6.7 Million   - Up 23% and Full-Year 20 20 Revenues of $ 2 1.8 Million   - Product Revenue Up 117% Conference call begins today at 8:30 am ET   YAVNE, Israel , Feb. 25, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company
View HTML
Toggle Summary MediWound Launches Clinical Development Program for Treatment of Non-Melanoma Skin Cancer
Phase I/II Clinical Study in Basal Cell Carcinoma Scheduled to Begin Second Quarter 2021, with Data Expected by the End of 2021 An Investigator-Initiated Trial Will Run in Parallel YAVNE, Israel , Feb. 22, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical
View HTML
Toggle Summary MediWound to Report Fourth Quarter and Fiscal 2020 Financial Results and Host a Conference Call and Webcast on February 25, 2021
YAVNE, Israel, Feb. 16, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that the Company will release its financial results for the fourth
View HTML
Toggle Summary MediWound to Participate in the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference
YAVNE, Israel , Feb. 10, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that Sharon Malka , Chief Executive Officer, will participate in a
View HTML
Toggle Summary MediWound Provides Progress Update on Its EscharEx Clinical Development Program
Phase 2 Adaptive Design Study Sample Size Reduced to 120 Patients Interim Assessment Expected in Mid-2021 and Completion of Enrollment by Year-End 2021 Protocol Submitted to FDA for Pharmacology Clinical Study with Data Expected in Second Half 2021 YAVNE, Israel , Jan.
View HTML